Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC

Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA